<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Eur. J. Cancer</journal-id><journal-title-group><journal-title>European Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0959-8049</issn><issn pub-type="epub">1879-0852</issn><publisher><publisher-name>Elsevier Science Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29128692</article-id><article-id pub-id-type="pmc">5729023</article-id><article-id pub-id-type="publisher-id">S0959-8049(17)31336-9</article-id><article-id pub-id-type="doi">10.1016/j.ejca.2017.09.033</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Crabb</surname><given-names>Simon J.</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Karen</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Abab</surname><given-names>Julia</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Ratcliffe</surname><given-names>Ian</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Thornton</surname><given-names>Roger</given-names></name><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Lineton</surname><given-names>Ben</given-names></name><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Ellis</surname><given-names>Mary</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Moody</surname><given-names>Ronald</given-names></name><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Stanton</surname><given-names>Louise</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Galanopoulou</surname><given-names>Angeliki</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Maishman</surname><given-names>Tom</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Geldart</surname><given-names>Thomas</given-names></name><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name><surname>Bayne</surname><given-names>Mike</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Davies</surname><given-names>Joe</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Lamb</surname><given-names>Carolynn</given-names></name><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author"><name><surname>Popat</surname><given-names>Sanjay</given-names></name><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author"><name><surname>Joffe</surname><given-names>Johnathan K.</given-names></name><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author"><name><surname>Nutting</surname><given-names>Chris</given-names></name><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author"><name><surname>Chester</surname><given-names>John</given-names></name><xref rid="aff11" ref-type="aff">k</xref></contrib><contrib contrib-type="author"><name><surname>Hartley</surname><given-names>Andrew</given-names></name><xref rid="aff12" ref-type="aff">l</xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Gareth</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Ottensmeier</surname><given-names>Christian</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Huddart</surname><given-names>Robert</given-names></name><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author"><name><surname>King</surname><given-names>Emma</given-names></name><email>E.King@soton.ac.uk</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>a</label>Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom</aff><aff id="aff2"><label>b</label>Poole Hospital NHS Foundation Trust, Poole, United Kingdom</aff><aff id="aff3"><label>c</label>Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom</aff><aff id="aff4"><label>d</label>NHS Research, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom</aff><aff id="aff5"><label>e</label>Institute of Sound and Vibration Research, University of Southampton, Southampton, United Kingdom</aff><aff id="aff6"><label>f</label>Patient and Public Involvement Representative, United Kingdom</aff><aff id="aff7"><label>g</label>Royal Bournemouth and Christchurch NHS Foundation Trust, Bournemouth, United Kingdom</aff><aff id="aff8"><label>h</label>The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom</aff><aff id="aff9"><label>i</label>Institute of Cancer Research and Royal Marsden Foundation Trust, London, United Kingdom</aff><aff id="aff10"><label>j</label>St James' University Hospital, Leeds, United Kingdom</aff><aff id="aff11"><label>k</label>College of Biomedical and Life Sciences, Cardiff University and Velindre Cancer Centre, Cardiff, United Kingdom</aff><aff id="aff12"><label>l</label>Queen Elizabeth Hospital, Birmingham, United Kingdom</aff><author-notes><corresp id="cor1"><label>&#x02217;</label><italic>Corresponding author</italic>: Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom.Cancer Sciences UnitUniversity of Southampton, SouthamptonUnited Kingdom <email>E.King@soton.ac.uk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>1</day><month>12</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.--><pub-date pub-type="ppub"><month>12</month><year>2017</year></pub-date><volume>87</volume><fpage>75</fpage><lpage>83</lpage><history><date date-type="received"><day>22</day><month>7</month><year>2017</year></date><date date-type="rev-recd"><day>22</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>25</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 The Authors</copyright-statement><copyright-year>2017</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Background</title><p>Cisplatin is one of the most ototoxic chemotherapy drugs, resulting in a permanent and irreversible hearing loss in up to 50% of patients. Cisplatin and gentamicin are thought to damage hearing through a common mechanism, involving reactive oxygen species in the inner ear. Aspirin has been shown to minimise gentamicin-induced ototoxicity. We, therefore, tested the hypothesis that aspirin could also reduce ototoxicity from cisplatin-based chemotherapy.</p></sec><sec><title>Methods</title><p>A total of 94 patients receiving cisplatin-based chemotherapy for multiple cancer types were recruited into a phase II, double-blind, placebo-controlled trial&#x000a0;and randomised in a ratio of 1:1 to receive aspirin 975&#x000a0;mg tid and omeprazole 20&#x000a0;mg od, or matched placebos from the day before, to 2 days after, their cisplatin dose(s), for each treatment cycle. Patients underwent pure tone audiometry before&#x000a0;and at 7 and 90 days after their final cisplatin dose. The primary end-point was combined hearing loss (cHL), the summed hearing loss at 6&#x000a0;kHz and 8&#x000a0;kHz, in both ears.</p></sec><sec><title>Results</title><p>Although aspirin was well tolerated, it did not protect hearing in patients receiving cisplatin (p-value&#x000a0;=&#x000a0;0.233, 20% one-sided level of significance). In the aspirin arm, patients demonstrated mean cHL of 49&#x000a0;dB (standard deviation [SD] 61.41) following cisplatin compared with placebo patients who demonstrated mean cHL of 36&#x000a0;dB (SD 50.85). Women had greater average hearing loss than men, and patients treated for head and neck malignancy experienced the greatest cHL.</p></sec><sec><title>Conclusions</title><p>Aspirin did not protect from cisplatin-related ototoxicity. Cisplatin and gentamicin may therefore have distinct ototoxic mechanisms, or cisplatin-induced ototoxicity may be refractory to the aspirin regimen used here.</p></sec></abstract><abstract abstract-type="author-highlights" id="abs0015"><title>Highlights</title><p><list list-type="simple"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Aspirin was well tolerated.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">Aspirin did not protect hearing at the doses and in the schedule investigated here.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">Cisplatin and gentamicin may have distinct ototoxic mechanisms.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">Qualitative data suggest protective aspirin effect&#x000a0;but low power for hypothesis.</p></list-item><list-item id="u0030"><label>&#x02022;</label><p id="p0030">Cisplatin-induced ototoxicity results in significant morbidity.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Cisplatin</kwd><kwd>Chemotherapy</kwd><kwd>Aspirin</kwd><kwd>Ototoxicity</kwd><kwd>Hearing</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0035">Cisplatin is a commonly used cytotoxic chemotherapeutic agent to treat a wide variety of cancer types, including head and neck, bladder, lung and germ-cell malignancies. In each of these diseases, cisplatin is used in curative as well as palliative treatment settings. Subsequently, adverse effects of treatment which are irreversible will potentially impact on patients for prolonged periods of time, thereby reducing health-related quality-of-life. Cisplatin has well-documented side-effects, including one of the highest rates of ototoxicity of all chemotherapy agents <xref rid="bib1" ref-type="bibr">[1]</xref>, <xref rid="bib2" ref-type="bibr">[2]</xref>. Cisplatin-related ototoxicity includes high-frequency bilateral and symmetrical hearing loss, which may be permanent and irreversible and is often associated with tinnitus <xref rid="bib2" ref-type="bibr">[2]</xref>, <xref rid="bib3" ref-type="bibr">[3]</xref>. Currently, there are no established methods to avoid or reverse cisplatin-related ototoxicity, other than dose reduction or switching to non-cisplatin regimens, which can have negative impacts on outcomes. Hence, ototoxicity risk must be weighed against oncological efficacy.</p><p id="p0040">Fifty percent of patients receiving a cumulative cisplatin dose of &#x0003e;200&#x000a0;mg/m<sup>2</sup> have a significant reduction in their hearing, with a severe to profound hearing loss in both ears <xref rid="bib2" ref-type="bibr">[2]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib6" ref-type="bibr">[6]</xref>: Using the American Speech&#x02013;Language&#x02013;Hearing Association criteria, this equates to&#x000a0;&#x0003e;&#x000a0;71&#x000a0;dB hearing loss, which clinically translates into the patient being aware of their hearing loss in most, if not all situations and only managing without a hearing aid if they concentrate and the speaker significantly raises their voice and if there are no competing sound sources <xref rid="bib2" ref-type="bibr">[2]</xref>.Clearly, this degree of hearing loss is very debilitating and may not always be appreciated by the clinician, on a one-to-one basis <xref rid="bib7" ref-type="bibr">[7]</xref>.</p><p id="p0045">Ototoxicity from cisplatin is thought to be due, in part, to reactive oxygen species (ROS); ROS can be attenuated by antioxidants, such as salicylates, including aspirin. Gentamicin and cisplatin are thought to have a similar ototoxic mechanism of action. ROS lead to S-Nitrosylation of cochlear proteins causing damage to the outer hair cells, supporting cells, marginal cells of the stria vascularis, spiral ligament&#x000a0;and the spiral ganglion cells <xref rid="bib8" ref-type="bibr">[8]</xref>. The outer hair cells in the basal turn of the cochlea are the most affected <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>, resulting in an initial elevation of high-frequency audiometric thresholds, followed by a progressive loss into the lower frequencies with continued therapy <xref rid="bib11" ref-type="bibr">[11]</xref>.</p><p id="p0050">Aspirin was shown to prevent gentamicin-induced hearing loss without compromising its anti-bacterial efficacy in both animal models and in the clinical setting <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>. Patients treated with 1&#x000a0;g tds aspirin for 14 days, in addition to gentamicin, as part of a randomised controlled trial (RCT), showed a significant reduction in hearing loss compared with patients receiving gentamicin alone <xref rid="bib12" ref-type="bibr">[12]</xref>. The incidence of significant hearing loss reduced from 13% in the placebo arm to 3% in the aspirin arm (relative risk 0.26, 95% confidence interval [CI] 0.08&#x02013;0.86).</p><p id="p0055">Aspirin has also been shown to protect hearing from cisplatin-induced ototoxicity in rats, using a breast cancer model <xref rid="bib14" ref-type="bibr">[14]</xref>. Protection of hearing was achieved without apparent loss of anti-tumour efficacy of cisplatin.</p><p id="p0060">We, therefore, sought to test if aspirin could reduce cisplatin-related hearing loss in a phase II RCT for patients treated with a variety of cisplatin-based systemic anti-cancer therapy regimens.</p></sec><sec id="sec2"><label>2</label><title>Patients and methods</title><p id="p0065">We performed a phase II RCT in patients receiving cisplatin-based chemotherapy in eight United Kingdom cancer centres.</p><p id="p0070">Patients were eligible if they were 18 years or older and deemed suitable for a chemotherapy regimen containing a cumulative cisplatin dose of &#x02265;200&#x000a0;mg/m<sup>2</sup>, with a maximum of two consecutive days cisplatin dosing per cycle, either as a single agent or as a combination chemotherapy. Key exclusion criteriaincluded were as follows: prior cisplatin treatment; diagnosis of nasopharyngeal or skull base carcinoma (other head and neck tumours allowed); treatment plan requiring cisplatin for more than two or on non-consecutive days of a treatment cycle; therapeutic aspirin &#x0003e;75&#x000a0;mg/day; prior history of haemorrhagic stroke, inflammatory bowel disease or haematological clotting disorders; absolute contraindication to aspirin/proton-pump inhibitors; symptomatic hearing loss which the PI considered excluded the use of cisplatin; pregnant/breast-feeding patients. Women of childbearing potential were required to have a negative pregnancy test performed within 7 days before trial drug administration, and all patients were required to use adequate birth control.</p><p id="p0075">Baseline hearing tests were recorded before receiving the first cisplatin dose and included pure tone audiometry (PTA) and otoacoustic emissions (OAEs). A new technique has enabled non-linear components of the OAE to be recorded <xref rid="bib15" ref-type="bibr">[15]</xref>, showing that both second- and third-order non-linear components (Volterra Kernels), vk21&#x02013;vk23 and vk31&#x02013;vk33, are much more sensitive to minor hearing system damage than conventionally recorded responses <xref rid="bib16" ref-type="bibr">[16]</xref>. These were repeated for 7 days (&#x000b1;3 days) after completion of the last cisplatin dose&#x000a0;and again at 90 days (&#x000b1;7 days) after treatment.</p><p id="p0080">Patients received up to six cycles of cisplatin-based chemotherapy, according to tumour site, response and toxicity. Aspirin at a dose of 975&#x000a0;mg tid, or placebo were administered orally, for 4 days in patients receiving cisplatin on a single day each cycle and for 5 days in patients receiving fractionated cisplatin chemotherapy on two consecutive days of each cycle (commencing the day before the first cisplatin administration, in both cases, to protect the hair cells from the cisplatin until it is bound to the plasma proteins&#x000a0;or cleared via the kidneys). Omeprazole 20&#x000a0;mg or matching placebo was taken orally, once daily on the same days as the aspirin/placebo (i.e. patients received either both drugs or both placebos).</p><p id="p0085">Blinding to drug/placebo allocation was achieved by formulation of a 975-mg enteric-coated aspirin tablet with a matched placebo. Omeprazole was sourced from the commercial market and over encapsulated using an opaque gelatin capsule. A matched placebo for the omeprazole tablet was also over encapsulated (NuPharm Laboratories Ltd, Flintshire, UK).</p><p id="p0090">The primary outcome was change in hearing loss during treatment (measurements taken before and at 7 days and 3 months after completion of cisplatin treatment) using PTA test at frequencies of 6&#x000a0;kHz and 8&#x000a0;kHz in both ears. Secondary outcome measures included assessment of other PTA test frequencies including 0.25, 0.5, 1, 2, 3 and 4&#x000a0;kHz at baseline and at 7 days and 3 months post-cisplatin; clinician-assessed level of hearing loss measured by the Common Toxicity Criteria for Adverse Events (CTCAE), version 4.03; OAE profile before and after treatment (at 7 days and 3 months post-cisplatin); safety profile assessment using CTCAE and with specific focus on gastrointestinal and renal toxicity; assessment of treatment and concomitant medication compliance&#x000a0;and cisplatin dose intensity.</p><p id="p0095">Trial conduct was in accordance with the principles outlined in the International Conference on Harmonisation Good Clinical Practice&#x000a0;guidelines and in compliance with the protocol, the Data Protection Act and all other ethical and regulatory requirements, as appropriate. Written informed consent was obtained from all study participants. The trial was sponsored by <funding-source id="gs7">University Hospital Southampton NHS Foundation Trust</funding-source> and coordinated by the Southampton Clinical Trials Unit. Funding was from <funding-source id="gs8">Cancer Research UK</funding-source> (C39812/A13344). EudraCT reference number: 2012-001509-25.</p></sec><sec id="sec3"><label>3</label><title>Statistical methods</title><p id="p0100">The primary outcome was combined hearing loss (cHL) in decibels, assessed as total post-treatment hearing after chemotherapy (the sum of PTA measurements at 6&#x000a0;kHz and 8&#x000a0;kHz in both ears at the first time point after their last cisplatin dose), adjusted for baseline total hearing. This was assessed in the intention-to-treat (ITT) cohort using an analysis of covariance (ANCOVA) model adjusted for treatment arm and the stratification factor cisplatin dose. In addition, a &#x02018;per-protocol cohort&#x02019; analysis and &#x02018;protected cisplatin cohort&#x02019; (each cisplatin cycle received was &#x02018;protected&#x02019; by either aspirin or placebo) analyses were planned as secondary outcomes.</p><p id="p0105"><xref rid="appsec1" ref-type="sec">Supplementary Document 1</xref> provides full details of the sample size. A total of 88 patients (44 per arm) were required, allowing for 80% power with a one-sided significance level of 20%. Patients were randomised using a web-based system on a 1:1 allocation, using block randomisation stratified by cisplatin dose.</p></sec><sec id="sec4"><label>4</label><title>Results</title><p id="p0110">A total of 439 patients were screened to allow 94 patients to be recruited to the trial (45 to aspirin and 49 to placebo): a reflection of block randomisation. Patients were recruited between 14-March-2013 and 09-July-2015, and were followed up for 3 months. The trial ended when a sufficient number of patients with baseline and at least one post-chemo PTA test were available. Reasons for screen failure are detailed in <xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>. Demographic characteristics (age, gender and ethnicity) and hearing at baseline were balanced between arms (<xref rid="tbl1" ref-type="table">Table 1</xref>). Planned and actual cisplatin dose administered were also balanced between arms; however, some minor imbalances were seen with respect to tumour site (<xref rid="tbl1" ref-type="table">Table 1</xref>). There were trends of more bladder tumours in the placebo arm (15 versus 8) and more head and neck tumours in the aspirin arm (21 versus 14). Median inter-cycle time was the same between both arms (21 days) and there were similar doses of cisplatin received and cisplatin dose intensity between the arms (data not shown). Of note, gastrointestinal problems reported at baseline were greater in the placebo arm (22% versus 4%).<fig id="fig1"><label>Fig.&#x000a0;1</label><caption><p>CONSORT diagram for cisplatin ototoxicity attenuated by aspirin trial (intent-to-treat population, n&#x000a0;=&#x000a0;94).</p></caption><alt-text id="alttext0035">Fig.&#x000a0;1</alt-text><graphic xlink:href="gr1"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Patient demographics and tumour groups (intent-to-treat population, n&#x000a0;=&#x000a0;94).</p></caption><alt-text id="alttext0045">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Aspirin (n&#x000a0;=&#x000a0;45)</th><th>Placebo (n&#x000a0;=&#x000a0;49)</th></tr></thead><tbody><tr><td colspan="3" align="left">Age at randomisation</td></tr><tr><td align="left">&#x000a0;Mean (SD)</td><td align="left">56.1 (11.20)</td><td align="left">60.0 (11.78)</td></tr><tr><td align="left">&#x000a0;Range</td><td align="left">24.0&#x02013;75.0</td><td align="left">27.0&#x02013;79.0</td></tr><tr><td colspan="3" align="left">Gender: n (%)</td></tr><tr><td align="left">&#x000a0;Female</td><td align="left">9 (20.0%)</td><td align="left">13 (26.5%)</td></tr><tr><td align="left">&#x000a0;Male</td><td align="left">36 (80.0%)</td><td align="left">36 (73.5%)</td></tr><tr><td colspan="3" align="left">Ethnicity: n (%)</td></tr><tr><td align="left">&#x000a0;White</td><td align="left">43 (95.6%)</td><td align="left">48 (98.0%)</td></tr><tr><td align="left">&#x000a0;Asian or Asian British</td><td align="left">0</td><td align="left">1 (2.0%)</td></tr><tr><td align="left">&#x000a0;Black or black British</td><td align="left">1 (2.2%)</td><td align="left">0</td></tr><tr><td align="left">&#x000a0;Not stated</td><td align="left">1 (2.2%)</td><td align="left">0</td></tr><tr><td colspan="3" align="left">Total baseline hearing<xref rid="tbl1fna" ref-type="table-fn">a</xref></td></tr><tr><td align="left">&#x000a0;N</td><td align="left">45</td><td align="left">48</td></tr><tr><td align="left">&#x000a0;Mean (SD)</td><td align="left">164.9 (70.93)</td><td align="left">170.2 (85.88)</td></tr><tr><td align="left">&#x000a0;Range</td><td align="left">&#x02212;5.0 to 295.0</td><td align="left">40.0&#x02013;385.0</td></tr><tr><td colspan="3" align="left">Planned cisplatin dose level: n (%)</td></tr><tr><td align="left">&#x000a0;&#x0003e;200&#x000a0;mg/m<sup>2</sup> but &#x0003c;300&#x000a0;mg/m<sup>2</sup></td><td align="left">22 (48.9%)</td><td align="left">24 (49.0%)</td></tr><tr><td align="left">&#x000a0;&#x0003e;300mg/m<sup>2</sup> but &#x0003c;400&#x000a0;mg/m<sup>2</sup></td><td align="left">11 (24.4%)</td><td align="left">13 (26.5%)</td></tr><tr><td align="left">&#x000a0;&#x0003e;400&#x000a0;mg/m<sup>2</sup></td><td align="left">12 (26.7%)</td><td align="left">12 (24.5%)</td></tr><tr><td colspan="3" align="left">Actual cisplatin dose level: n (%)</td></tr><tr><td align="left">&#x000a0;&#x0003e;200&#x000a0;mg/m<sup>2</sup> but &#x0003c;300&#x000a0;mg/m<sup>2</sup></td><td align="left">22 (48.9%)</td><td align="left">22 (44.9%)</td></tr><tr><td align="left">&#x000a0;&#x0003e;300&#x000a0;mg/m<sup>2</sup> but &#x0003c;400mg/m<sup>2</sup></td><td align="left">12 (26.7%)</td><td align="left">13 (26.5%)</td></tr><tr><td align="left">&#x000a0;&#x0003e;400&#x000a0;mg/m<sup>2</sup></td><td align="left">11 (24.4%)</td><td align="left">14 (28.6%)</td></tr><tr><td colspan="3" align="left">Tumour group: n (%)</td></tr><tr><td align="left">&#x000a0;Bladder carcinoma</td><td align="left">8 (17.8%)</td><td align="left">15 (30.6%)</td></tr><tr><td align="left">&#x000a0;Germ cell</td><td align="left">7 (15.6%)</td><td align="left">5 (10.2%)</td></tr><tr><td align="left">&#x000a0;Head and neck</td><td align="left">21 (46.7%)</td><td align="left">14 (28.6%)</td></tr><tr><td align="left">&#x000a0;Lung</td><td align="left">9 (20.0%)</td><td align="left">15 (30.6%)</td></tr><tr><td align="left">Number of patients who withdrew before treatment: n (%)</td><td align="left">2 (4.4%)</td><td align="left">1 (2.0%)</td></tr><tr><td align="left">Number of patients who completed planned<xref rid="tbl1fnb" ref-type="table-fn">b</xref> treatment: n (%)</td><td align="left">23 (51.1%)</td><td align="left">25 (51.0%)</td></tr></tbody></table><table-wrap-foot><fn><p>SD, standard deviation.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0010">Total baseline hearing is the sum of pure tone audiometry measurements at 6&#x000a0;kHz and 8&#x000a0;kHz in both ears before their first cisplatin dose.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntpara0015">Planned treatment regimen (number of cisplatin cycles) as on baseline electronic Case Report Form (eCRF).</p></fn></table-wrap-foot></table-wrap></p><p id="p0115">Patient follow-up is shown in <xref rid="appsec1" ref-type="sec">Supplementary Table 1</xref>, detailing per-protocol and cisplatin-protected groups: 32 (71%) of the aspirin arm and 34 (69%) of the placebo arm attended both follow-up visits for PTA and OAE testing. Twenty-four patients also underwent OAE testing at baseline (aspirin: 9 and placebo: 15), which showed a bigger range of OAE in the placebo arm, but this was not significant (data not shown).</p><p id="p0120">There was a difference between one or more days delay in chemotherapy administration between the arms 15 of 45 (33.3%) for the aspirin arm compared with 21 of 49 (42.9%) for placebo, resulting in 19 and 30 delayed cisplatin cycles, respectively. The individual reasons are outlined in <xref rid="appsec1" ref-type="sec">Supplementary Table 2</xref>. Reasons for patients stopping treatment early are outlined in <xref rid="appsec1" ref-type="sec">Supplementary Table 3</xref> and show that these were similar between both arms.</p><p id="p0125">Up to 75&#x000a0;mg per day of therapeutic aspirin was permitted for trial entry: Four patients (8%) of the placebo arm and six patients (13%) of the aspirin arm were taking up to 75&#x000a0;mg of aspirin at baseline: this had dropped to one patient for both arms at follow-up.</p><sec id="sec4.1"><label>4.1</label><title>Primary end-point</title><p id="p0130">The primary end-point was cHL at 6&#x000a0;kHz and 8&#x000a0;kHz. In the ITT population, there was a mean cHL of 49.0&#x000a0;dB (n&#x000a0;=&#x000a0;39; standard deviation [SD] 61.41) and 36.0&#x000a0;dB (n&#x000a0;=&#x000a0;40; SD 50.85) in the aspirin&#x000a0;and placebo arms, respectively. In the ANCOVA model, total post-treatment hearing was compared between the two arms after adjusting for total hearing at baseline and cisplatin dose level. There was no evidence to suggest that aspirin protects hearing (least squares mean difference&#x000a0;=&#x000a0;9.38 [60% CI: &#x02212;1.45&#x000a0;to 20.22; p-value&#x000a0;=&#x000a0;0.233 at a 20% one-sided level of significance]; <xref rid="tbl2" ref-type="table">Table 2</xref>).<table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Analysis of covariance of combined hearing loss&#x000a0;(first post-chemotherapy pure tone audiometry hearing test) (intent-to-treat population, n&#x000a0;=&#x000a0;79).</p></caption><alt-text id="alttext0050">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th colspan="4">Statistic</th></tr></thead><tbody><tr><td align="left">Least squares means</td><td align="left">Estimate</td><td align="left">Difference</td><td align="left">60% CI of LS mean</td><td align="left">One-sided p-value<xref rid="tbl2fna" ref-type="table-fn">a</xref></td></tr><tr><td align="left">&#x000a0;Aspirin (n&#x000a0;=&#x000a0;39)</td><td align="left">218.80</td><td rowspan="2" align="left">9.38</td><td rowspan="2" align="left">(&#x02212;1.45&#x000a0;to 20.22)</td><td rowspan="2" align="left">0.233</td></tr><tr><td align="left">&#x000a0;Placebo (n&#x000a0;=&#x000a0;40)</td><td align="left">209.40</td></tr><tr><td align="left">Model coefficients</td><td align="left">Estimate</td><td colspan="2" align="left">60% CI</td><td align="left">Two-sided p-value</td></tr><tr><td align="left">Aspirin arm</td><td align="left">9.38</td><td colspan="2" align="left">(&#x02212;1.45 to 20.22)</td><td align="left">0.466</td></tr><tr><td align="left">Placebo arm</td><td align="left">0 (Ref)</td><td colspan="2" align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Intercept</td><td align="left">61.22</td><td colspan="2" align="left">(42.90&#x02013;79.54)</td><td align="left">0.006</td></tr><tr><td align="left">Total hearing at baseline</td><td align="left">0.85</td><td colspan="2" align="left">(0.78&#x02013;0.92)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">Dose level: &#x02265;200&#x000a0;mg/m<sup>2</sup> but &#x0003c;300&#x000a0;mg/m<sup>2</sup></td><td align="left">7.48</td><td colspan="2" align="left">(&#x02212;5.58 to 20.54)</td><td align="left">0.629</td></tr><tr><td align="left">Dose level: &#x02265;300&#x000a0;mg/m<sup>2</sup> but &#x0003c;400&#x000a0;mg/m<sup>2</sup></td><td align="left">&#x02212;2.23</td><td colspan="2" align="left">(&#x02212;17.20 to 12.74)</td><td align="left">0.900</td></tr><tr><td align="left">Dose level: &#x02265;400&#x000a0;mg/m<sup>2</sup></td><td align="left">0 (Ref)</td><td colspan="2" align="left">&#x02013;</td><td align="left">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn><p>CI, confidence interval; ANCOVA, analysis of covariance; LS, least squares; PTA, pure tone audiogram.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fna"><label>a</label><p id="ntpara0020">Combined hearing loss assessed using ANCOVA model: Total post-treatment hearing post-chemotherapy (the sum of PTA measurements at 6&#x000a0;kHz and 8&#x000a0;kHz in both ears at the first time point after their last cisplatin dose)&#x000a0;=&#x000a0;intercept&#x000a0;+&#x000a0;treatment arm&#x000a0;+&#x000a0;total hearing at baseline (the sum of PTA measurements at 6&#x000a0;kHz and 8&#x000a0;kHz in both ears before their first cisplatin dose)&#x000a0;+&#x000a0;randomisation stratification factor dose of cisplatin.</p></fn></table-wrap-foot></table-wrap></p><p id="p0135">No evidence of statistically significant differences in total post-treatment hearing between aspirin&#x000a0;and placebo arms was observed in the per-protocol or protected cisplatin populations (p-values&#x000a0;=&#x000a0;0.300 and 0.344, respectively at a 20% one-sided level of significance; data not shown).</p></sec><sec id="sec4.2"><label>4.2</label><title>Secondary end-points</title><p id="p0140">At 90 days after completion of cisplatin chemotherapy, the cHL remained in the aspirin arm with a mean loss of 63.9&#x000a0;dB (n&#x000a0;=&#x000a0;27; SD 52.59) and 37.3&#x000a0;dB (n&#x000a0;=&#x000a0;30; SD 49.94) in the placebo arm. It can be seen (<xref rid="fig2" ref-type="fig">Fig.&#x000a0;2</xref>) that there was no substantial change in the cHL between days 7 and 90 (correlation coefficient equal to 0.95 [i.e. day 7 and day 90]). Hearing loss does not correlate with cisplatin dose (&#x02265;200&#x000a0;mg/m<sup>2</sup> but &#x0003c;300&#x000a0;mg/m<sup>2</sup>, &#x02265;300&#x000a0;mg/m<sup>2</sup> but &#x0003c;400&#x000a0;mg/m<sup>2</sup> or &#x02265;400&#x000a0;mg/m<sup>2</sup>). Additional <italic>ad hoc</italic> analysis, dividing patients at baseline into normal and mild hearing&#x000a0;and moderate or worse hearing showed that the better the initial hearing, the greater the subsequent hearing loss (<xref rid="appsec1" ref-type="sec">Supplementary Fig.&#x000a0;1</xref>). However, there was no difference in ototoxic protection between these different hearing groups with aspirin or placebo (data not shown). In addition, age did not predict for hearing loss in these data&#x000a0;although the sample size may preclude meaningful conclusion. In our data set, women lost more hearing than men (<xref rid="appsec1" ref-type="sec">Supplementary Fig.&#x000a0;2</xref>) and&#x000a0;patients receiving cisplatin for head and neck cancer&#x000a0;experienced the largest median hearing loss (<xref rid="appsec1" ref-type="sec">Supplementary Fig.&#x000a0;3</xref>). OAE data confirm the PTA data (<xref rid="appsec1" ref-type="sec">Supplementary Table 4</xref>).<fig id="fig2"><label>Fig.&#x000a0;2</label><caption><p>Scatter plot to assess the relationship between the first and second pure tone audiometry hearing assessment values (intent-to-treat population provided two post-chemotherapy values, n&#x000a0;=&#x000a0;57).</p></caption><alt-text id="alttext0040">Fig.&#x000a0;2</alt-text><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec4.3"><label>4.3</label><title>Safety end-points</title><p id="p0145">From the ITT population, 88.9% (40 of 45) of aspirin and 95.9% (47 of 49) of placebo patients experienced at least one adverse event (<xref rid="appsec1" ref-type="sec">Supplementary Table 5</xref>). Renal toxicity affected more patients in the aspirin arm (17.8% versus 10.2%) although the majority of these were CTCAE, version 4.03, grade I or II (<xref rid="appsec1" ref-type="sec">Supplementary Table 6</xref>): By contrast, renal and serum biochemistry values did not appear to be altered by the administration of aspirin or placebo (<xref rid="appsec1" ref-type="sec">Supplementary Table 7</xref>).</p><p id="p0150">Interestingly, reported gastrointestinal toxicities were similar between arms; supporting the use of proton pump inhibitors to minimise any gastrointestinal toxicities. In addition, hearing toxicities were greater in the placebo arm (44.9% versus 28.9%; <xref rid="tbl3" ref-type="table">Table 3</xref>).<table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p>Hearing toxicity experienced during the trial period by CTCAE grade (intent-to-treat population, n&#x000a0;=&#x000a0;94).</p></caption><alt-text id="alttext0055">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Aspirin (n&#x000a0;=&#x000a0;45)</th><th>Placebo (n&#x000a0;=&#x000a0;49)</th></tr></thead><tbody><tr><td align="left">Number of patients who experienced at least one hearing AE: n (%)<xref rid="tbl3fna" ref-type="table-fn">a</xref></td><td align="left">13 (28.9%)</td><td align="left">22 (44.9%)</td></tr><tr><td colspan="3" align="left">Hearing adverse events: n (%)<xref rid="tbl3fna" ref-type="table-fn">a</xref></td></tr><tr><td align="left">&#x000a0;CTCAE, version 4.03 grade I or II</td><td align="left">13 (28.9%)</td><td align="left">22 (44.9%)</td></tr><tr><td align="left">&#x000a0;CTCAE, version 4.03 grade III or above</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Severe, life-threatening or death-related hearing adverse events (CTCAE, version 4.0 grade III or above): n (%)<xref rid="tbl3fna" ref-type="table-fn">a</xref></td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">&#x000a0;Inner ear toxicity</td><td align="left">0</td><td align="left">0</td></tr></tbody></table><table-wrap-foot><fn><p>AE, adverse event; CTCAE, Common terminology criteria for adverse events.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fna"><label>a</label><p id="ntpara0025">If a patient experienced more than one hearing AE with different CTCAE grades, then the worst CTCAE grade is counted in this table.</p></fn></table-wrap-foot></table-wrap></p><p id="p0155">There were 20 of 22 (90.9%) and 22 of 24 (91.7%)&#x000a0;aspirin&#x000a0;and placebo arm patients, respectively, reported as having serious adverse events (SAEs), but only two patients were reported as experiencing serious adverse reactions (SARs).</p></sec></sec><sec id="sec5"><label>5</label><title>Discussion</title><p id="p0160">Aspirin was well tolerated but did not protect hearing in patients when combined with cisplatin chemotherapy. Aspirin was protective in a prior study of patients receiving gentamicin (although describing a different primary end-point), suggesting that either cisplatin and gentamicin have distinct ototoxic mechanisms (and aspirin would not have been protective at any dose)&#x000a0;or cisplatin in the cumulative doses required for most cancer indications, is perhaps more ototoxic, requiring larger (and potentially impractical) or prolonged protective doses <xref rid="bib12" ref-type="bibr">[12]</xref>. As an antimicrobial agent, gentamicin is expected to reach a relatively steady state in contrast with cisplatin, which relies on a maximally tolerated dose; which leads us to the possibility that perhaps an increased aspirin dose to compensate for this would have provided ototoxic protection. In addition, the question of aspirin-related ototoxicity should be raised although it is unlikely to result in any permanent or irreversible ototoxicity at the short duration administered in this trial <xref rid="bib17" ref-type="bibr">[17]</xref>. With regard to duration of aspirin administration, we chose to evaluate a 4- or 5-day schedule starting 24&#x000a0;h prior, until 2 days after, cisplatin on each cycle. The rationale for this approach was to optimise aspirin exposure to the duration of peak cisplatin exposure. The clearance of total platinum from plasma is rapid during the first 4&#x000a0;hours&#x000a0;after intravenous administration and decays monoexponentially with a half-life of about 20&#x02013;30&#x000a0;minutes&#x000a0;following bolus administrations of 50 or 100&#x000a0;mg/m<sup>2</sup> doses. However, there is then a prolonged low exposure to plasma protein&#x02013;bound platinum that may persist for many years after cisplatin administration and might potentially account for a failure to address acute ototoxicity through the approach tested here <xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib19" ref-type="bibr">[19]</xref>, <xref rid="bib20" ref-type="bibr">[20]</xref>.</p><p id="p0165">It is interesting that, despite the negative PTA and OAE (<xref rid="appsec1" ref-type="sec">Supplementary Table 4</xref>) results, hearing toxicity, as perceived by patients, was significantly worse in the placebo arm (<xref rid="tbl3" ref-type="table">Table 3</xref>). At this time, PTA is the gold standard for quantifying hearing loss. However, we accept that it does not capture qualitative, patient-related outcome, and this may explain the reported differences.</p><p id="p0170">Our data did not show any significant deterioration in the acute setting between day 7 and day 90 (<xref rid="fig2" ref-type="fig">Fig.&#x000a0;2</xref>). This contrasts with previously published data that have shown increased hearing loss after completion of cisplatin over a chronic time course over many months and years, which has been explained by the long-term (up to 20 years) retention of this compound <xref rid="bib19" ref-type="bibr">[19]</xref>, <xref rid="bib20" ref-type="bibr">[20]</xref>. It is feasible that continued follow-up of our patient cohort could have demonstrated this chronic continued deterioration that we did not identify in the acute setting.</p><p id="p0175">Patients with better hearing at baseline were at greater relative risk of hearing loss following cisplatin (<xref rid="appsec1" ref-type="sec">Supplementary Fig.&#x000a0;1</xref>). This is likely to reflect the number of functional hair cells that can potentially be destroyed by cisplatin in those patients with good hearing <xref rid="bib14" ref-type="bibr">[14]</xref>. This may be important clinically as cisplatin might tend to be avoided, based on treatment guidelines, in patients with pre-existent poor hearing to minimise the risk of further deterioration. However, the greatest risk of harm, in absolute terms, may in fact reside with those patients with good hearing initially. This is perhaps counterintuitive to many clinicians in their approach to the use of cisplatin in routine practice, and guidelines should be considered for this patient group.</p><p id="p0180">Women suffered greater hearing loss than men (<xref rid="appsec1" ref-type="sec">Supplementary Fig.&#x000a0;2</xref>). Previous papers have published hearing loss data associated with cisplatin in discrete disease types (i.e. gynaecological and testicular cancers) where gender differences would not have been highlighted <xref rid="bib21" ref-type="bibr">[21]</xref>, <xref rid="bib22" ref-type="bibr">[22]</xref>. However, a rat model supports our gender difference by demonstrating adult female rat predisposition to increased cisplatin toxicity: this resulted in an increased audiometric loss and histopathological correlation, reflecting increased damage in the spiral ganglion and brainstem of female rats <xref rid="bib23" ref-type="bibr">[23]</xref>. By contrast, in the paediatric population, boys are four times more likely to suffer from cisplatin-induced ototoxicity than girls, perhaps reflecting hormonal protection <xref rid="bib24" ref-type="bibr">[24]</xref>.</p><p id="p0185">It is well established that an increasing dose of cisplatin is associated with an increasing risk of ototoxicity <xref rid="bib11" ref-type="bibr">[11]</xref>. In contrast to this and to the data recently published <xref rid="bib2" ref-type="bibr">[2]</xref>, cisplatin dose in our cohort did not correlate with ototoxic potential. In the Frisina germ-cell cohort, greater or less than 300&#x000a0;mg/m<sup>2</sup> cisplatin stratified patients into severity of hearing loss <xref rid="bib2" ref-type="bibr">[2]</xref>. It is likely that our smaller sample size, across multiple tumour types, contributed to this lack of effect.</p><p id="p0190">We demonstrated that head and neck cancer patients&#x000a0;experienced the largest median hearing loss (<xref rid="appsec1" ref-type="sec">Supplementary Fig.&#x000a0;3</xref>): This may have resulted from the concomitant radiotherapy that this patient population would also have received, which despite cochlear sparing (Intensity Modulated Radiotherapy, IMRT) protocols, may still induce a degree of cochlear damage <xref rid="bib25" ref-type="bibr">[25]</xref>, <xref rid="bib26" ref-type="bibr">[26]</xref>. Although this is unlikely to have introduced significant bias into the trial, it is important to highlight that there were more head and neck patients in the aspirin arm and more bladder patients in the placebo arm. Despite being a younger cohort with better baseline hearing, germ-cell patients surprisingly did not show worse hearing loss (<xref rid="appsec1" ref-type="sec">Supplementary Fig.&#x000a0;3</xref>).</p></sec><sec id="sec6"><label>6</label><title>Conclusion</title><p id="p0195">Although aspirin was well tolerated, it did not protect hearing at the doses and in the schedule investigated here, suggesting that cisplatin and gentamicin may have distinct ototoxic mechanisms or that cisplatin is more ototoxic, requiring larger protective doses. Qualitative data did suggest a protective effect of aspirin, but this trial was not powered to test this hypothesis. Cisplatin-induced ototoxicity results in significant morbidity, and further research is required to devise options to prevent it.</p></sec><sec id="sec7"><title>Conflict of interest statement</title><p id="p0220">None declared.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Anniko</surname><given-names>M.</given-names></name><name><surname>Sobin</surname><given-names>A.</given-names></name></person-group><article-title>Cisplatin: evaluation of its ototoxic potential</article-title><source>Am J Otolaryngol</source><volume>7</volume><issue>4</issue><year>1986</year><fpage>276</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">3752388</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Frisina</surname><given-names>R.D.</given-names></name><name><surname>Wheeler</surname><given-names>H.E.</given-names></name><name><surname>Fossa</surname><given-names>S.D.</given-names></name><name><surname>Kerns</surname><given-names>S.L.</given-names></name><name><surname>Fung</surname><given-names>C.</given-names></name><name><surname>Sesso</surname><given-names>H.D.</given-names></name></person-group><article-title>Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer</article-title><source>J Clin Oncol</source><volume>34</volume><issue>23</issue><year>2016 Aug 10</year><fpage>2712</fpage><lpage>2720</lpage><pub-id pub-id-type="pmid">27354478</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>J.L.</given-names></name><name><surname>Adelstein</surname><given-names>D.J.</given-names></name><name><surname>Newman</surname><given-names>C.W.</given-names></name><name><surname>Rybicki</surname><given-names>L.A.</given-names></name><name><surname>Rice</surname><given-names>T.W.</given-names></name><name><surname>Lavertu</surname><given-names>P.</given-names></name></person-group><article-title>Cisplatin ototoxicity: the importance of baseline audiometry</article-title><source>Am J Clin Oncol</source><volume>22</volume><issue>3</issue><year>1999</year><fpage>305</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">10362343</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Vermorken</surname><given-names>J.B.</given-names></name><name><surname>Kapteijn</surname><given-names>T.S.</given-names></name><name><surname>Hart</surname><given-names>A.A.</given-names></name><name><surname>Pinedo</surname><given-names>H.M.</given-names></name></person-group><article-title>Ototoxicity of cisdiamminedichloroplatinum (II): influence of dose, schedule and mode of administration</article-title><source>Eur J Cancer Clin Oncol</source><volume>19</volume><issue>1</issue><year>1983</year><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">6682776</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Fausti</surname><given-names>S.A.</given-names></name><name><surname>Schechter</surname><given-names>M.A.</given-names></name><name><surname>Rappaport</surname><given-names>B.Z.</given-names></name></person-group><article-title>Early detection of cisplatin ototoxicity. Selected case reports</article-title><source>Cancer</source><volume>53</volume><issue>2</issue><year>1984</year><fpage>224</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">6537798</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Moroso</surname><given-names>M.J.</given-names></name><name><surname>Blair</surname><given-names>R.L.</given-names></name></person-group><article-title>A review of cis-platinum ototoxicity</article-title><source>J Otolaryngol</source><volume>12</volume><issue>6</issue><year>1983</year><fpage>365</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">6686617</pub-id></element-citation></ref><ref id="bib7"><label>7</label><mixed-citation publication-type="other" id="sref7">Age UK <ext-link ext-link-type="uri" xlink:href="http://www.ageukhearingaids.co.uk" id="intref0015">www.ageukhearingaids.co.uk</ext-link>.</mixed-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="book" id="sref8"><person-group person-group-type="author"><name><surname>Chirtes</surname><given-names>F.</given-names></name><name><surname>Albu</surname><given-names>S.</given-names></name></person-group><chapter-title>Prevention and restoration of hearing loss associated with the use of cisplatin</chapter-title><year>2014</year><publisher-name>Biomed Research International</publisher-name><comment>Article ID 925485</comment></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Callejo</surname><given-names>A.</given-names></name><name><surname>Sedo-Cabezon</surname><given-names>L.</given-names></name><name><surname>Juan</surname><given-names>I.</given-names></name><name><surname>Llorens</surname><given-names>J.</given-names></name></person-group><article-title>Cisplatin-induced ototoxicity: effects, mechanisms and protective strategies</article-title><source>Toxics</source><volume>3</volume><issue>3</issue><year>2015</year><fpage>268</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">29051464</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Rybank</surname><given-names>L.P.</given-names></name><name><surname>Ramkumar</surname><given-names>V.</given-names></name></person-group><article-title>Ototoxicity</article-title><source>Kidney Int</source><volume>72</volume><issue>8</issue><year>2007</year><fpage>931</fpage><lpage>935</lpage><pub-id pub-id-type="pmid">17653135</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Paken</surname><given-names>J.</given-names></name><name><surname>Govender</surname><given-names>C.D.</given-names></name><name><surname>Pillay</surname><given-names>M.</given-names></name><name><surname>Sewram</surname><given-names>V.</given-names></name></person-group><article-title>Cisplatin-associated ototoxicity: a review for the health professional</article-title><source>iBooks/Journal Toxicol</source><year>2016</year><object-id pub-id-type="publisher-id">180934</object-id><comment>13 pages</comment></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Sha</surname><given-names>S.H.</given-names></name><name><surname>Qiu</surname><given-names>J.H.</given-names></name><name><surname>Schacht</surname><given-names>J.</given-names></name></person-group><article-title>Aspirin to prevent gentamicin-induced hearing loss</article-title><source>N Engl J Med</source><volume>354</volume><issue>17</issue><year>2006 27</year><fpage>1856</fpage><lpage>1857</lpage><pub-id pub-id-type="pmid">16641409</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>W.G.</given-names></name><name><surname>Zha</surname><given-names>D.J.</given-names></name><name><surname>Qiu</surname><given-names>J.H.</given-names></name><name><surname>Wang</surname><given-names>J.L.</given-names></name><name><surname>Sha</surname><given-names>S.H.</given-names></name></person-group><article-title>Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic</article-title><source>Hear Res</source><volume>226</volume><issue>1&#x02013;2</issue><year>2007</year><fpage>178</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">16844331</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Sha</surname><given-names>S.H.</given-names></name><name><surname>Zotova</surname><given-names>E.</given-names></name><name><surname>Arezzo</surname><given-names>J.</given-names></name><name><surname>Van de Water</surname><given-names>T.</given-names></name><name><surname>Schacht</surname><given-names>J.</given-names></name></person-group><article-title>Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action</article-title><source>LabInvest</source><volume>82</volume><issue>5</issue><year>2002</year><fpage>585</fpage><lpage>596</lpage></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Thornton</surname><given-names>A.R.D.</given-names></name><name><surname>Shin</surname><given-names>K.</given-names></name><name><surname>Gottesman</surname><given-names>E.</given-names></name><name><surname>Hine</surname><given-names>J.</given-names></name></person-group><article-title>Temporal nonlinearities of the cochlear amplifier revealed by maximum length sequence stimulation</article-title><source>Clin Neurophysiol</source><volume>112</volume><year>2001</year><fpage>768</fpage><lpage>777</lpage><pub-id pub-id-type="pmid">11336891</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Thornton</surname><given-names>A.R.D.</given-names></name><name><surname>Lineton</surname><given-names>B.</given-names></name><name><surname>Baker</surname><given-names>V.J.</given-names></name><name><surname>Slaven</surname><given-names>A.</given-names></name></person-group><article-title>Nonlinear properties of optoacoustic emissions in normal and impaired hearing</article-title><source>Hear Res</source><volume>219</volume><year>2006</year><fpage>56</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">16839724</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Sheppard</surname><given-names>A.</given-names></name><name><surname>Hayes</surname><given-names>S.H.</given-names></name><name><surname>Chen</surname><given-names>G.D.</given-names></name><name><surname>Ralli</surname><given-names>M.</given-names></name><name><surname>Salvi</surname><given-names>R.</given-names></name></person-group><article-title>Review of salicylate-induced hearing loss, neurotoxicity, tinnitus and neuropathophysiology</article-title><source>Acta Otorhinolaryngol Ital</source><volume>34</volume><issue>2</issue><year>2014 Apr</year><fpage>79</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">24843217</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="book" id="sref18"><person-group person-group-type="author"><name><surname>Medicines.org.uk</surname></name></person-group><chapter-title>Cisplatin 1 mg/ml Sterile Concentrate - Summary of Product Characteristics (SPC) - (eMC)</chapter-title><year>2017</year><comment>[Accessed 22 September 2017]</comment><ext-link ext-link-type="uri" xlink:href="http://www.medicines.org.uk/emc/medicine/623" id="intref0020">http://www.medicines.org.uk/emc/medicine/623</ext-link></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Sprauten</surname><given-names>M.</given-names></name><name><surname>Darrah</surname><given-names>T.H.</given-names></name><name><surname>Peterson</surname><given-names>D.R.</given-names></name><name><surname>Campbell</surname><given-names>M.E.</given-names></name><name><surname>Hannigan</surname><given-names>R.E.</given-names></name><name><surname>Cvancarova</surname><given-names>M.</given-names></name></person-group><article-title>Impact of long-term serum platinum concentrations on neuro and ototoxicity in cisplatin-treated survivors of testicular cancer</article-title><source>J Clin Oncol</source><volume>30</volume><year>2012</year><fpage>300</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">22184390</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Brouwers</surname><given-names>E.E.</given-names></name><name><surname>Huitema</surname><given-names>A.D.</given-names></name><name><surname>Beijnen</surname><given-names>J.H.</given-names></name><name><surname>Schellens</surname><given-names>J.H.</given-names></name></person-group><article-title>Long-term platinum retention after treatment with cisplatin-treated survivors of testicular cancer</article-title><source>BMC Clin Pharmacol</source><volume>8</volume><year>2008</year><fpage>7</fpage><pub-id pub-id-type="pmid">18796166</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Bokemeyer</surname><given-names>C.</given-names></name><name><surname>Berger</surname><given-names>C.C.</given-names></name><name><surname>Hartmann</surname><given-names>J.T.</given-names></name><name><surname>Kollmannsberger</surname><given-names>C.</given-names></name><name><surname>Schmoll</surname><given-names>H.J.</given-names></name><name><surname>Kuczyk</surname><given-names>M.A.</given-names></name></person-group><article-title>Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer</article-title><source>Br J Cancer,</source><volume>77</volume><issue>8</issue><year>1998</year><fpage>1355</fpage><lpage>1362</lpage><pub-id pub-id-type="pmid">9579846</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Melamed</surname><given-names>L.B.</given-names></name><name><surname>Selim</surname><given-names>A.</given-names></name><name><surname>Schuchman</surname><given-names>D.</given-names></name></person-group><article-title>Cisplatin ototoxicity in gynaecologic cancer patients. A preliminary report</article-title><source>Cancer</source><volume>55</volume><issue>no. 1</issue><year>1985</year><fpage>41</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">4038376</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Kirkim</surname><given-names>G.</given-names></name><name><surname>Olgun</surname><given-names>Y.</given-names></name><name><surname>Aktas</surname><given-names>S.</given-names></name><name><surname>Kiray</surname><given-names>M.</given-names></name><name><surname>Kolatan</surname><given-names>E.</given-names></name><name><surname>Altun</surname><given-names>Z.</given-names></name></person-group><source>Eur Arch Otorhinolaryngol</source><volume>272</volume><issue>10</issue><year>2015 Oct</year><fpage>275</fpage><lpage>363</lpage></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Yancey</surname><given-names>A.</given-names></name><name><surname>Harris</surname><given-names>M.S.</given-names></name><name><surname>Egbelakin</surname><given-names>A.</given-names></name><name><surname>Gilbert</surname><given-names>J.</given-names></name><name><surname>Pisoni</surname><given-names>D.B.</given-names></name><name><surname>Renbarger</surname><given-names>J.</given-names></name></person-group><article-title>Risk factors for cisplatin-associated ototoxicity in paediatric oncology patients</article-title><source>Pediat Blood Cancer</source><year>2012</year><fpage>144</fpage><lpage>148</lpage></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Bhandare</surname><given-names>N.</given-names></name><name><surname>Jackson</surname><given-names>A.</given-names></name><name><surname>Eisbruch</surname><given-names>A.</given-names></name><name><surname>Pan</surname><given-names>C.C.</given-names></name><name><surname>Flickinger</surname><given-names>J.C.</given-names></name><name><surname>Antonelli</surname><given-names>P.</given-names></name></person-group><article-title>Radiation therapy and hearing loss</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>76</volume><issue>3 Suppl</issue><year>2010 Mar 1</year><fpage>S50</fpage><lpage>S57</lpage><pub-id pub-id-type="pmid">20171518</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Hitchcock</surname><given-names>Y.J.</given-names></name><name><surname>Tward</surname><given-names>J.D.</given-names></name><name><surname>Szabo</surname><given-names>A.</given-names></name><name><surname>Bentz</surname><given-names>B.G.</given-names></name><name><surname>Shrieve</surname><given-names>D.C.</given-names></name></person-group><article-title>Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>73</volume><issue>3</issue><year>2009 Mar 1</year><fpage>779</fpage><lpage>788</lpage><comment>Epub 2008 Aug 15</comment><pub-id pub-id-type="pmid">18707819</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0210">The following are the supplementary data related to this article:<supplementary-material content-type="local-data" id="mmc1"><caption><title>mmc1</title></caption><media xlink:href="mmc1.docx"><alt-text>mmc1</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><title>mmc2</title></caption><media xlink:href="mmc2.docx"><alt-text>mmc2</alt-text></media></supplementary-material><fig id="dfig1" position="anchor"><label>Supplementary Fig.&#x000a0;1</label><caption><p>Box-and-Whisker plot of hearing loss between baseline and first post-chemotherapy pure tone audiometry hearing test by baseline hearing category (intent-to-treat population, n&#x000a0;=&#x000a0;94).</p></caption><alt-text id="alttext0020">Supplementary Fig.&#x000a0;1</alt-text><graphic xlink:href="figs1"/></fig><fig id="dfig2" position="anchor"><label>Supplementary Fig.&#x000a0;2</label><caption><p>: Box-and-Whisker plot of hearing loss&#x000a0;between baseline and first post-chemotherapy pure tone audiometry hearing test by gender (intent-to-treat population, n&#x000a0;=&#x000a0;94).</p></caption><alt-text id="alttext0025">Supplementary Fig.&#x000a0;2</alt-text><graphic xlink:href="figs2"/></fig><fig id="dfig3" position="anchor"><label>Supplementary Fig.&#x000a0;3</label><caption><p>: Box-and-Whisker plot of hearing loss between baseline and first post-chemotherapy pure tone audiometry hearing test by tumour group (intent-to-treat population, n&#x000a0;=&#x000a0;94).</p></caption><alt-text id="alttext0030">Supplementary Fig.&#x000a0;3</alt-text><graphic xlink:href="figs3"/></fig></p></sec><ack id="ack0010"><title>Acknowledgements</title><p>This work was supported by <funding-source id="gs1">Cancer Research UK</funding-source> (C39812/A13344. <funding-source id="gs3">CRUK</funding-source> Trial number CRUK/11/047. EudraCT ref number: 2012-001509-25) and <funding-source id="gs2">Cancer Research UK</funding-source> core funding from the Southampton Clinical Trials Unit. The authors thank the patients who participated in the trial and the <funding-source id="gs4">NIHR Clinical Research Network</funding-source> (Cancer) who supported the trial. They also acknowledge the support of the <funding-source id="gs5">NIHR Royal Marsden</funding-source> and <funding-source id="gs6">Institute of Cancer Research Biomedical Research Centre</funding-source>.</p><p>ISRCTN Registry Clinical Trial Registration Number: ISRCTN83689269.</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0215">Supplementary data related to this article can be found at <ext-link ext-link-type="doi" xlink:href="10.1016/j.ejca.2017.09.033" id="intref0010">https://doi.org/10.1016/j.ejca.2017.09.033</ext-link>.</p></fn></fn-group></back></article>